**CURRICULUM VITAE**

**Date of Revision: September 8, 2024**

**Name: Michael D. Virata, MD, FACP, FIDSA**

**Proposed for Promotion to: Associate Professor of Clinical Medicine, Department of Medicine,**

**Section of Infectious Diseases, Clinical Track, with a Secondary**

**Appointment in the Yale School of Nursing**

**Term: July 1, 2020 – June 30, 2025**

**School: Yale School of Medicine**

**Reason for Promotion:**

**Education:**

A.B. University of the Philippines (Humanities, Pre-Med), cum laude, 1984

M.D. University of the Philippines School of Medicine, 1989

**Career/Academic Appointments:**

1990-1991 Intern, Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD

1991-1993 Assistant and Senior Resident, Sinai Hospital of Baltimore, Baltimore, MD

1993-1996 Postdoctoral Fellow in Infectious Diseases, Yale University School of Medicine, New Haven, CT

1996-1997 Postdoctoral Fellow in Medical Microbiology, Yale University School of Medicine, New Haven, CT

1998-2002 Clinical Instructor, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

2002-2014 Assistant Clinical Professor, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

2014-2018 Clinician, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

2018-2020 Assistant Professor of Clinical Medicine, Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT

2019-present Associate Clinical Professor, Yale School of Nursing, New Haven CT

2020-present Associate Professor of Clinical Internal Medicine (Term), Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT

**Administrative Positions**

1998-2001 Director, HIV Division, Cornell Scott-Hill Health Center, New Haven, CT

2009-2012 Director, HIV Services, Hospital of Saint Raphael, New Haven, CT

2011-2023 Supervising Director, Ryan White Program at Saint Raphael Campus of YNHH

2009-2012 Medical Director, The Haelen Center, Hospital of Saint Raphael, New Haven, CT

2012-2014 Director, HIV Services, Saint Raphael Campus, Yale-New Haven Hospital, New Haven, CT

2014-2023 Director, HIV Services, Saint Raphael Campus, Yale School of Medicine, New Haven, CT

2014-2023 Medical Director, Haelen-Infectious Disease Center, Saint Raphael Campus, Yale-New Haven Hospital

2021-present Program Director, HIV Care and Prevention Program, Yale-New Haven Hospital

2023-present Medical Director, HIV Care and Prevention, Yale Center for Infectious Disease, Yale-New Haven Hospital

**Clinical Responsibilities**

2001-2012 Direct Outpatient HIV care at the Haelen Center, Hospital of Saint Raphael, New Haven, CT

2012-2023 Direct Outpatient HIV care at the Haelen Center, Saint Raphael Campus of Yale-New Haven Hospital, New Haven, CT

2023-present Direct Outpatient HIV Care at the Yale Center for Infectious Diseases, Yale-New Haven Hospital, New Haven, CT.

Includes Program Director for Ryan White Part B. Lead agency model for New Haven County, CT

Section of Infectious Diseases

2021-present Lead, CQM committee, Ryan White Part A, New Haven-Fairfield EMA

**Board Certification**

2022 American Academy of HIV Medicine (Specialist)

2016 American Board of Internal Medicine, Infectious Diseases

2010 American Society of Tropical Medicine and Hygiene

2007 American Board of Internal Medicine, Internal Medicine

Certificate courses

2022 Stanford School of Business – LGBTQ+ Executive Leadership Course

**Professional Honors & Recognition**

**International/National/Regional**

2023 Elsie Cofield Award for Community Service, New Haven Mayor’s Task Force on HIV/AIDS

2021 Elected Fellow of the Infectious Disease Society of America

2012 Preceptorship to the National HIV/AIDS Clinicians’ Consultation Center, sponsored by the Northeast AIDS Education and Training Center, University of California at San Francisco

2012 & 2009 Vincent T. Andriole Award for Basic Research in Infectious Diseases, CT ID Society Meeting

2009 Research Attending Physician of the Year, Hospital of Saint Raphael

2008 Elected Fellow of the American College of Physicians

2003 George Thorton MD Award for Clinical Science in Infectious Diseases, CT ID Society Meeting

1995 Scholarship for the SHEA/CDC/AHA training course in Hospital Epidemiology, October

1993 Resident of the Month, Sinai Hospital of Baltimore, January

2001 Nominated for the Departmental Award for Excellence in Teaching Ambulatory Medicine to Medical Students, Yale School of Medicine

1984 Phi Kappa Phi International Honors Society, Philippine chapter

1984 Cum laude, AB, University of the Philippines

1980-84 Consistent college scholar, University of the Philippines

# Grant/Clinical Trials History

**Current Grants:**

Title: Emerging Strategies to Improve Health Outcomes for People Aging with HIV: Demonstration sites (I-CARE-4PAH)

Agency: HRSA-22-028

Role: Sub-investigator, Evaluator (PI: Lydia Barakat and Julie Womack)

Percent effort: 10%

Project period: August 2022-2025

Total Funding: $300,000/year

Title: Region 1 Ryan White Part B Core & Support Services Partnership

Agency: CT DPH

Role: Program Director, under Yale-New Haven Hospital HIV Care and Prevention Program

Percent effort: 10%

Project Period: April 2022-March 2026

Total Funding: $6,979,291.00 (1,744,822.75/year)

**Current Clinical Trials:**

Agency: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

HIC# 090005730

Title: Reduced Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention

Role: Yale Site Sub-Investigator (L. Fiellin, PI)

Percent effort: 1%

Project period:03/01-2015-present

Total Funding: $734,346.00

Agency: National Cancer Institute/NIH/DHHS

HIC#: 1406014146 LD# R01CA206483

Title: Pathogenesis and treatment of HIV-associated disease

Role: Yale Site Sub-Investigator (B. Emu, PI)

Percent effort: 1%

Project period: 7/11/2014-present

Total Funding: $3,014,885

Agency: National Cancer Institute/NIH/DHHS

HIC#: 1407014364 LD# R01CA206483

Title: Cancers in Individuals with HIV Infection

Role: Yale Site Sub-Investigator (B. Emu, PI)

Percent effort: 1%

Project period: 7/25/2014-present

Total Funding: $3,014,885

**Past Grants**

2009 Investigator Initiated grant from Cubist Pharmaceuticals to study MRSA susceptibility to daptomycin

Date: 2009-2011

Total Award: $25,000.00

2005 Educational Program Grant Award for HIV Epidemiology, Treatment and Research (GSK)

Date: 10/2005-4/2006

Total Award: $5,000.00

**Past Clinical Trials:**

Agency: General Hospital Corporation; Massachusetts General Hospital

HIC 1501015241

Title: REPRIEVE (A5332) - Randomized Trial to Prevent Vascular Events in HIV (The REPRIEVE Study)

Role: Yale Site Sub-Investigator

Percent effort: 1%

Project period: 02/19/2015-2023

Per Patient Fee: $3,486.00

|  |  |  |
| --- | --- | --- |
| Agency: Contrafect Corporation | |  |
| HIC#2000027366 |  |
| Title:A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose | | |

of Exebacase in Adult Patients Receiving Standard-of-Care Antibiotics for the Treatment of

*Staphylococcus aureus* Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis(The DISRUPT Study).

Role: Yale Site Principal Investigator

Percent effort: 2%

Project period: 2020 to Dec 2022.

Per Patient Fee: $17,192.00

Agency: Proteus Digital Health

HIC#: 2000022189

Title: Impact of the Proteus Discover digital medicine service on adherence and sustained virologic response rates in patients with chronic Hepatitis C infection treated with direct-acting agents Role: Yale Site Sub-Investigator (M. Villanueva, PI)

Percent effort: 1%

Project period: 12/14/2017-2020

Total Funding: None

Agency: Leonard-Meron Biosciences, Inc.

HIC#2000022741

Title: A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Mino-Lok Therapy (MLT) in Combination with Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infections.

Role: Yale Site Principal Investigator

Percent effort: 1%

Project period: 6/14/2018-4/15/2021

Per Patient Fee: $13,536.00

Agency: Contrafect Corporation

HIC#200002294

Title:A Multicenter Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for the Treatment of Adult Patients with Staphylococcus aureus Bloodstream Infections (Bacteremia) Including Endocarditis. Enrollment completed, data analysis completed.

Role: Yale Site Principal Investigator

Percent effort: 2%

Project period: 5/23/2018 to 7/19/2019

Per Patient Fee: $29,840.00

Agency: Shionogi Inc.

HIC#2000022296

Title:A Multicenter, Randomized, Double-blind Parallel group, Clinical Study of S-649266 Compared with

Meropenem for the Treatment of Hospital-Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens. Enrollment completed, data analysis completed.

Role: Yale Site Principal Investigator

Percent effort: 2%

Project period: 3/6/2018 to 7/9/2019

Per Patient Fee: $23,526.00

Agency: Yale

HIC#1606017976

Title:Rapid Referral for HIV Linkage to Care; Patients with a new HIV+ diagnosis who were linked to care within a fast track system assisted by the Early Intervention Services program as part of a RW Part A Grant and were compared outcomes with another group of newly diagnosed individuals with what was deemed as those involved with the current standard (SOC) for linking patients into HIV care. Role: Principal Investigator

Percent effort: 1%

Project Period: 6/21/2016 to 7/2/2019

Total Funding: None

Agency: Merck Inc. (Cubist prior to buyout)

HIC#160801186

Title: A prospective, randomized, double-blind, multicenter, Phase 3 study to assess the safety and efficacy of intravenous ceftolozane/tazobactam compared with meropenem in adult patient with ventilated nosocomial pneumonia (the ASCPECT-NP Trial) – Enrollment completed, data analysis completed. FDA approval was given for this indication in 2019.

Role: Yale Site Principal Investigator

Percent effort: 2%

Project Period: 10/4/2016 to 6/1/2018

Per Patient Fee: $25,964.00

Agency: Gilead GS-US-366-1160

HIC# 1502015358

Title: Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of

Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects. Trial completed.

Role: Yale Site Sub-Investigator (M. Kozal, PI)

Percent effort: 1%

Project period: 02/19/15-07/02/2018

Per Patient Fee: $10,446.00

Agency: Gilead GS-US-366-1216

HIC #1502015373

Title: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of

Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1

Positive Subjects who are Virologically-Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate . Trial completed

Role: Yale Site Sub-Investigator (M. Kozal, PI)

Percent effort: 1%

Project period: 02/19/15-07/18/2018

Per Patient Fee: $8,819.00

Agency: Bristol-Myers-Squibb Research and Development

HIC# 1502015357

Title: A Multi-arm, Phase 3, Randomized, Placebo controlled, Double-Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects with Mutli-drug Resistant HIV-1. Trail Completed.

Role: Yale Site Sub-Investigator (M. Kozal, PI)

Percent effort: 1%

Project period: 03/20/15-06/29/2018

Per Patient Fee: $11,431.00

Agency: Bristol-Myers-Squibb Research and Development

HIC# 1503015534

Title: BMS AI468-038 - A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate

Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in

Treatment-Naïve HIV-1 Infected Adults -Trial Completed

Role: Yale Site Sub-Investigator (M. Kozal, PI)

Percent effort: 1%

Project period: 03/20/15-03/22/2016

Per Patient Fee: $14,000.00

**Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated with Yale:**

**International**

2016 Department of Internal Medicine Grand Rounds

‘The HIV Care Continuum: It Starts with You”

University of the Philippines College of Medicine

Philippine General Hospital, Manila, Philippines

2014 University of the Philippines Medical Alumni Society

‘Boosting your Chances’

Manila, Philippines

**National**

2014 Invited Speaker – Geisinger Health Systems

MRSA Bacteremia: Is Vancomycin Enough? The MI-C of Change.

Danville, PA

2014 University of the Philippines Medical Alumni Society of America Annual Convention,

‘Boosting your Chances’ San Diego, CA

2012 Invited Speaker –The 7th Annual MAI-NEHEC Multicultural HIV/AIDS Provider Summit

The DCU Center, Worcester, MA

2012 Medical Grand Rounds

Clinical Challenges for MRSA Bacteremia: Fix or Fail

University of South Carolina, Columbia, South Carolina

**Regional**

2024 Invited Speaker, CT ID Society Annual Meeting, Waterbury CT. Confirmed Virologic Failure in a Patient on Long-Acting cabotegravir+rilpivirine with On-Time dosing and the development of cabotegravir resistance

2024 Invited Speaker, Northeast AIDS Education Training Center, CROI 2024 Update

2024 Invited Speaker, Northeast AIDS Education Training Center, CoP, UConn-Yale

2023 Integrating Whole-Person Care to End the Syndemic: A Quality Improvement (QI) Summit. Approach to Oral Health Screening: Process Map for Oral Health Services (CQM)

2023 Northeast AIDS Education Training Center, CT statewide Grand Rounds – Approach to the Care of Cis-gen Men.

2022 Northeast AIDS Education Training Center and the CT DPH, TPOXX for Monkeypox (Treatment)

2022 Northeast AIDS Education Training Center, Monkeypox Update

2022 Northeast AIDS Education Training Center and the CT DPH, EHE Statewide Summit (Diagnosis)

2021 Invited Speaker, CT Infectious Disease Society Annual Meeting “PrEP Clinical Update 2021”

|  |  |  |
| --- | --- | --- |
| 2020 | Northeast AIDS Education Training Center, “16th HIV & Aging During the COVID-19 pandemic: Title of the talk “Intersection of HIV and COVID-19”. Virtual program. | |
| 2020 | CT AIDS Education Training Center, “Ending the HIV Epidemic”. Virtual program |  |

2019 CT Department of Public Health, 4th PreP Symposium, “Clinical Update on PrEP 2019”. Rocky

Hill, CT

2015 CT Department of Public Health 2nd PrEP Summit, YNHH PrEP Program and Protocol Update, Preliminary results. Meriden, CT

2014 CT Department of Public Health 1st PrEP Summit, YNHH PrEP Program and Protocol: The Beginning. Meriden, CT

2011 Invited Panelist – HIV cases; CT ID Society Meeting, West Haven, CT.

2009 HIV Educational Forum sponsored by the Mayor’s Task Force of Bristol CT, Mayor’s Task force

2008 Guest Speaker, CT Latino Council on HIV/AIDS, Case presentation

2008,2004 Invited Speaker - CT AIDS Education and Training Center, providing updates for the HIV provider community

2004 Guest Speaker, American Health Resource Pharmacy Update, Farmington CT. Title: “HIV/AIDS: Emerging Issues in Assessment and Treatment”

2002 Guest Speaker, Albany Medical College, May 2002, Title “Once Daily Dosing for HIV and Complications arising from New HIV Therapy”

2002 Guest Speaker, Connecticut Association of Philippine Physicians Semi-Annual Meeting, Mohegan Sun Resort. Title: HIV-The Plague of the 21st Century

**Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated with Yale-New Haven Health System:**

**International/National**

2024: Womack J, Johnson C, Danvers K, Hsieh E, Lauro M, Marottoli R, Murphy A, Payne E, Sheehan L, Stewart W, **Virata M**, Barakat L. Baseline Patient and Clinician Results for the Pilot Project I-CARE-4-PAH (Intervention for Collaborative Care to Assess Risk and Eliminate Polypharmacy, Falls, ad Fragility Fractures for People Aging with HIV). Poster Presentation. IDWeek 2024. Los Angeles, CA. October 2024.

**Virata M**, Maughan A. Approach to Improving Oral Health Screenings Thru the Use of A Process Map and Ishikawa Diagram. Poster Presentation. 2024 National Ryan White Conference on HIV Care & Treatment. Washington, DC. August 2024.

Womack J, Barakat L, **Virata M** et al. Initial Results for the Pilot Project: I-CARE-4PAH. Poster Presentation. 2024 National Ryan White Conference on HIV Care & Treatment. Washington, DC. August 2024.

Lee B, Rotter LK, Pischel L, Spichler-Moffarah A, **Virata M**. When One Is Not Enough - A Curious Case of Diffuse Osseous Abscesses. Clinical Grand Rounds Presentation. European Congress of European Society of Clinical Microbiology and Infectious Diseases/ Barcelona, Spain. April 2024.

2023: Achhra A, Chan E, Applebaum S, Guerrero M, Hao R, Pantel H, **Virata M**, Barakat L. Evaluation of Anal Cancer Screening Program in men who have sex with men (MSM) persons with HIV. (PWH) At Two academic center HIV Clinics 2018-2022. Poster presentation, IDWeek 2023, Boston, MA. October 2023.

Foppiano-Palacios C, Achhra A, Barakat L, **Virata M**, Hao R, Baxter JD, Malinis M. Is there value in performing yearly screening for later tuberculosis infection by interferon-gamma release assay among patients living with HIV in non-endemic settings? Poster presentation, IDWeek 2023, Boston, MA. October 2023,

2021: Gleeson S, Bathgate M, Frederick J, Desruisseaux M, Meyer J, **Virata M**, Zapata H, Shenoi S, Radin J, Golden M, Trubin P, Shaw A, Friedland G, Aoun-Barakat L. Infectious Disease Diversity, Equity, and Antiracism (ID2EA): A Dedicated Curriculum for Infectious Disease Professionals. Accepted for an oral presentation for IDWeek 2021. Virtual.

2021: **Virata M**, Villanueva M, Miceli J. Targeted HIV Testing for Patients Hospitalized for COVID-19. Accepted for a poster presentation for IDWeek 2021. Virtual.

2020: **Virata M**, Sheenoi S, Villanueva M, Ladines J, Aoun-Barakat L. Outcomes related to COVID-19 Among People Living with HIV: Cohort From a Large Academic Center. Accepted for an oral presentation for IDWeek 2020. Virtual.

2020: **Virata M**, Shenoi S, Villanueva M, Ladines J, Aoun-Barakat L. SARS-CoV-2 Viral Dynamics For Symptomatic People Living with HIV Requiring Hospitalization For COVID-19. Accepted for poster presentation for IDWeek 2020. Virtual.

|  |  |
| --- | --- |
|  |  |
| 2018: | Cudahy P, Comia C, **Virata M**. Earlier Linkage and ART Initiation Via Fast Track Referral System for New HIV Patients Leads to Stronger Engagement and Better Outcomes. Accepted for poster presentation for IDWeek 2018. San Francisco, CA. |
| 2018: | Cudahy P, Comia C, **Virata M.** Outcomes from a novel rapid referral, link and ART programme for newly diagnosed HIV positive patients. Accepted for a mini-oral/e-poster presentation to the European Congress for Clinical Microbiology and Infectious Diseases. Madrid, Spain, April 2018 |

|  |  |
| --- | --- |
| 2015: | Hysell K, Barakat L, **Virata M**, Emu B. "Lung Cancer in Patients with HIV at a Single Institution in the Antiretroviral Era". Accepted for a poster presentation to the International Conference on Malignancies in AIDS and other Acquired Immunodeficiencies (ICMAOI) Bethesda, MD. |
| 2015: | Holmes J, Williams K, Stewart W, **Virata M**, Ogbuagu O Barakat L. Early Successful  Implementation of an HIV PrEP Program in Urban Academic Ambulatory HIV Clinic Settings. Accepted for a poster presentation to the 2015 National HIV Prevention Conference, Atlanta, GA, December 2015. |
| 2014: | Lombo B, Fotjadhi I, Ravi S, Golden, M, **Virata M**, Leviano M, Diez J, Ghantous A, Donahue T.  Prevalence of Metabolic Syndrome in Patients with HIV in the Era of Highly Active Antiretroviral Therapy. Accepted for poster presentation at the World Congress of Cardiology, Melbourne, Australia, May 2014. |
| 2013: | Moise P, Culshaw D Wong-Beringer A, Bensman J, Lamp K, Smith W, Bauer K, Goff D, Adamson  R, Leuthner K, **Virata M**, McKinnell J, Chaudry S, Eskandarian R and Zervos, M. Effectiveness of  Daptomycin (D) for MRSA Bloodstream Infections (BSI) with Vancomycin (V) MIC 1.5-2.0 mg/L: A Multicenter Evaluation of Clinical and Microbiologic Outcomes. Accepted for a poster presentation to the Joint Meeting of the IDSA, PIDS and SHEA (IDWeek), San Francisco, CA, October 2013. |
| 2013: | Moise P, Culshaw D Wong-Beringer A, Bensman J, Lamp K, Smith W, Bauer K, Goff D, Adamson  R, Leuthner K, **Virata M**, McKinnell J, Chaudry S, Eskandarian R and Zervos, M. Patterns of Antibiotic Utilization for MRSA Bloodstream Infections (BSI) with Vancomycin (V) MIC 1.5-2.0 mg/L:A Multicenter Evaluation. Accepted for a poster presentation to the Joint Meeting of the IDSA, PIDS and SHEA (IDWeek), San Francisco, CA, October 2013. Accepted for an oral presentation to the CT ID Society Meeting, May 2014, Orange, CT. |
| 2013: | Kfoury R, Sakoulas G, Nizet V and **Virata M**. Statin Therapy and MRSA Bacteremia: Effects on Staphyloxanthin formation and Clinical Outcomes. Accepted for a poster presentation to the Joint Meeting of the IDSA, PIDS and SHEA (IDWeek), San Francisco, CA. October 2013. |
| 2013: | Suarez R, Sadigh M, Igwe C, Chia D, Khan N, Aronin S, **Virata, M**. Imported Malaria: Barriers to Prompt Diagnosis and Treatment from Four Hospitals in Connecticut. Accepted for a poster presentation at the Joint Meeting of the IDSA, PIDS and SHEA (IDWeek), San Francisco, CA. October 2013. |
| 2013: | **Virata M**, Havill N, Sakoulas G. Non-susceptible Daptomycin Methicillin-Resistant  Staphylococcus aureus Isolates Associated with Reduced Susceptibility to Host Defense Cationic Peptides. Accepted for a poster presentation to the joint meeting of the IDSA, PIDS and SHEA (IDWeek), San Francisco, CA. October 2013. |
| 2013: | **Virata M**, Havill N, Otter J, Monecke S, Sakoulas G. DNA Microarray-based Genotyping of  Methicillin-Resistant Staphylococcus aureus Isolates in Patients with Bacteremia and Evidence of  Antimicrobial Resistance from 1998-2008. Accepted for a poster presentation to the Joint |

Meeting of the IDSA, PIDS and SHEA, October 2012, San Diego, CA and at the annual CT ID Society Meeting, West Haven, CT, May 2013.

|  |  |
| --- | --- |
| 2013: | **Virata M**, Monecke S, Sakoulas G. Comparative Molecular Epidemiology by DNA Microarray analysis of Clinical MRSA Isolates from Patients with Bacteremia Demonstrating Daptomycin Non-Susceptibility. Accepted for a poster presentation at the 113th ASM General Meeting, May 2013, Denver, CO. |
| 2012: | **Virata M**, Havill N, Otter J, Sakoulas G. Comparing Staphylococcus aureus staphyloxanthin pigment production among Bloodstream Isolates with Vancomycin MICs and Clone type from a Community Hospital. Accepted for a poster presentation at the 112th ASM General Meeting, June 2012, San Francisco, CA. |
| 2012: | Otter J, Havill N, **Virata M**. Vancomycin MIC and clone type are independent predictors of persistent MRSA bacteraemia at a US hospital. Accepted for a poster presentation for the 2012 European Congress of Clinical Microbiology and Infectious Diseases, London, UK and to the CT ID Society Meeting, May 2012. |
| 2012: | **Virata, M**, Boyce JM, Havill NL, Sakoulas G. Correlation between Vancomycin, Daptomycin and Telavancin MICs, *agr* function and Carotenoid Production among Diverse Isolates from Patients with MRSA Bloodstream Infections. Accepted for poster presentation at the 51st ICAAC meeting, Chicago, IL, Sept. 2011 and the CT ID Society meeting, Vincent T. Andriole Award for  Basic Science Research, May 2012 |
| 2011: | **Virata M**, Havill N. In-vitro Activity of Telavancin And Other Antimicrobials Against Isolates from Methicillin-resistant Staphylococcus aureus Bloodstream Infections from HIV(+) Patients With and Without Past Exposure to Vancomycin. Accepted for poster presentation for the 111th General Meeting ASM, New Orleans, LA, May 2011. |
| 2009: | **Virata M**, Abrokwah F, Havill N, Boyce JM. Vancomycin MICs, Heteroresistance, Clinical Features and Mortality for Hospitalized Patients with Persistent and Non-Persistent MRSA Bacteremia. Accepted for poster presentation to the 47th annual meeting of the IDSA, Philadelphia, PA, Oct 2009. |
| 2009: | **Virata M**, Havill N, Boyce JM. Acquisition of MRSA in Hospitalized Patients Resulting in Persistent Bacteremia: Molecular Epidemiology and Phenotypic Characteristics. Accepted for poster presentation to the 19th SHEA meeting, San Diego CA, March 2009. |
| 2009: | **Virata M**, Havill N, Boyce JM. Vancomycin MICs, Delta Hemolysin Production and  Heteroresistance among MRSA Isolates from Patients with Prolonged Bacteremia. Accepted for poster presentation to the 48th ICAAC/46th IDSA joint meeting, Washington DC, Oct 2008. (Vincent T. Andriole Award for Basic Science Research, CT ID Society meeting, May 2009 |
| 2006: | Tauman AV, **Virata M**, Boyce JM. Implementation of a criteria-based anti-infective approval system through computerized physician order entry (CPOE), Accepted for poster presentation to the 41st ASHP Clinical Meeting, Anaheim, California, Dec 2006. |
| 2003: | Backman L, Brett-Smith H, **Virata M**. Knowledge and Attitude Related to Plasma HIV RNA Levels and CD4 Cell Counts in HIV Infected Individuals: A Patient Perspective Study. Abstract accepted for poster presentation at the XIV International AIDS Conference, Barcelona, Spain. July 2002 and the CT Infectious Disease Society Meeting, 2003. |
| 1996: | **Virata M**, Tirell-Peck S, Meek J, Ryder R, Delbene J, Messmer T, Skelton S, Talkington D, Tacker L, Fields B, Butler J. Comparison of Serology and Throat Swab PCR for Diagnosis of Chlamydia pneumoniae and Mycoplasma pneumoniae among Outpatients with Pneumonia. Abstract accepted for poster presentation at the IDSA meeting. New Orleans, LA. |
| 1993: | **Virata M**, Kummer L, Kendig N. Medical Management of Tuberculosis Resistant to Isoniazid, Rifampin, and Pyrazinamide in a State Correctional System. Abstract accepted for poster presentation at the IDSA meeting. New Orleans, LA. |

**Regional**

2022**:** Achhra A, Canarie J, Paranandi A, **Virata M.** (Webinar)TPOXX for Monkeypox: A Practical Guide to Prescribing. Sponsored by the NEAETC. Oct 2022 by Zoom.

|  |  |
| --- | --- |
| 2015: | Ogbuagu O, Holmes J, Stewart W, **Virata M**, Barakat L. Implementation of an HIV Pre-exposure prophylaxis (PrEP) program within an outpatient HIV clinic: Early observations from the first 5 months. Accepted for an oral presentation to the CT ID Society Meeting, Orange, CT. |
| 2013: | **Virata M**, Hao R, Golden M, Fisher A, Marte C, Amico C, Hill R, Wilson L. Protecting Patients from *Pneumocystis jiroveci* Pneumonia. Presented at the annual Joseph A. Zaccanigno Conference for Patient Safety and Outcomes. New Haven, CT, May 1, 2013. |
| 2010: | **Virata M**, Blanco M, Havill N, Boyce JM. Distribution of Daptomycin and Vancomycin MICs and Clinical Characteristics in HIV (+) and HIV (-) patients with MRSA Bloodstream Infections.  Accepted for poster presentation at the 50th ICAAC meeting, Boston MA, Sept. 2010. |
| 2006: | Slim H, Shenoi S, **Virata, M**. A Rare Case of Community-Acquired MRSA Causing Necrotizing Bronchopneumonia, Epidural Abscess and Meningitis. Accepted for poster presentation to the Fall meeting for the CT Chapter of the ACP. |
| 2006: | Abreu-Lanfranco O, Nader C, **Virata, M**. The Use of Drug Resistance Testing Prior to the  Initiation of cART in HIV+ Treatment-Naive Patients. Accepted for poster presentation to the CT  Infectious Disease Society Meeting. |
| 2006: Alelis K, Palumbo J, Baltimore R, Meek J, Fazio D, **Virata M**, Heimer R. Hospital-Centered, Population-Based Surveillance for Pneumonia in New Haven, CT April 2004-March 2005.  Accepted for poster presentation to the CT Infectious Disease Society Meeting. | |

2004: Suarez J, Abreu-Lanfranco O, **Virata M**. HIV+ Patient with An Endobronchial Carcinoid Tumor. Accepted for poster presentation to the CT Chapter ACP meeting.

**Advisory Boards**

2018-2022 ViiV Pharmaceuticals

2017,2020 Gilead Sciences, Inc.

**Journal Services**

2022-2023 Academic Editor - PLOSOne

2008 Reviewer – Clinical Infectious Diseases

**Professional Service for Professional Organizations:**

***Professional Society Memberships***

2021-present American Medical Association

2022 - Alternate Delegate, CT Delegation

2016 to present European AIDS Clinical Society

2016 to present Connecticut State Medical Society

2022-present - Alternate Delegate to AMA, CT/NE Delegation

2016-present - Member, Public Health Committee

2022 Co-chair - LGBTQIA+ Affairs Ad-hoc committee

2016 to present New Haven County Medical Association

Member, Executive Committee,

President (2020-2021)

President-elect (2019-2020)

Member, Board of Governors

President, NHCMA Foundation (2021-2022)

2011 to present European Society of Clinical Microbiology and Infectious Diseases, Member

2000 to present International AIDS Society

1994 to present Infectious Diseases Society of America

Includes the HIV Medical Association (HIVMA)

2011 to 2015 Royal Society of Medicine, Overseas Fellow

2004 to 2008 American Society of Tropical Medicine and Hygiene

2007 to 2023 American Academy for HIV Medicine

1995 to 2023 Connecticut Infectious Diseases Society

1990 to present American College of Physicians/American Society of Internal Medicine

2008 Elected as a Fellow

1997 to 2016 American Society for Microbiology

1994-1996 American Association for the Advancement of Science

1995-1997 Society of Healthcare Epidemiologists of America

1992-2001,

Lifetime member Connecticut Association of Philippine Physicians

Lifetime member Philippine Medical Association

***Professional Service***

2021-2023 National actHIVation Steering Committee, Janssen Pharmaceuticals

**Yale University Service:**

***Medical School Committees***

2021-present Dean’s Advisory Council for LGBTQI Affairs

Faculty Advisor, 2022-present

Co-Leader, Clinical Care working group

2021-2022 Trans Specific Issues Affinity Group

2015-present EBE/DEI Committee, Yale School of Medicine

Member, Subcommittee for Faculty Recruitment

***Department of Medicine Committees***

2018-2019 Yale Clinical Optimization Service (ID)

2014-present Clinical Competency Committee (Section of ID), Yale School of Medicine

***Hospital and Community committees:***

2022-present Pride Health Council – Office of Health Equity

2022-present Signature Care Pathways for STIs, IE, Mpox for Ambulatory settings, Anal Dysplasia for HIV patients in the Ambulatory setting

2020-present YNHH Infection Control Committee, Alternate Member (ID)

2011-present Committees under **the Ryan White Part A** Programs

2011-present Member, Executive Committee, Primary Care Committee

2012-2014 Chairperson, EIS Subcommittee

2021-present Lead, Clinical Quality Management Committee

**Public Service:**

2024 Consultant for RFP Review of CT ADAP PBM funding, DPH

2022-present Vice President, Project Access New Haven

2021-present Alternate Delegate (New Haven County, CT) to the New England Delegation of the AMA

Member, Academic Physicians Section of the AMA

2020-present CT State Medical Society,

Council Member

Member, Public Health Committee, CT State Medical Society

Co-chair, Ad-hoc Committee, LGBTQIA+ Affairs

Project Access New Haven

Member, Board of Directors

2012-2022 Immediate Past President, New Haven County Medical Association

President, New Haven County Medical Association Foundation

2020-2021 President, New Haven County Medical Association

2019-2020 President-elect for New Haven County Medical Association

Chairperson, Nominating Committee, New Haven County Medical Association

2019Thesis Advisor for PA candidate, Vincenzo Julian, Yale School of Medicine, Yale University, New Haven, CT

2018 Preceptor/Mentor for the Internship of Lisa Sheehan, MPH Candidate, University of New England, Portland, ME

2017-present Member, New Haven Mayor’s Task Force for HIV/AIDS (appointed)

2014 Thesis Advisor for MPH candidate, Michael Ordazzo, Southern Connecticut State

University, New Haven, CT

2002 Thesis Advisor for MPH degree of Lauren Backman RN, Quinnipiac University, New Haven, CT

2014-present Medical Consultant, HIV Services, Leeway Inc.

**Bibliography:**

**Peer-Reviewed Original Research**

1. Perkins B, Flood J, Danila R, Holam R, Reingold A, Klug L, **Virata M**, Cieslak P, Zaki S, Pinner R, Khabbaz R, and the Unexplained Deaths Working Group. Unexplained Deaths Due to Possibly Infectious Causes in the United States: Defining the Problem and Designing Surveillance and Laboratory Approaches. Emerging Infectious Diseases. 1996; 2:47-53.
2. Frankel R, **Virata M**, Hardalo C, Altice F, Friedland G. Invasive Pneumococcal Disease

Seroprevalence, Antimicrobial Resistance, and Recurrence Rates in HIV (+) and HIV (-) Patients. Clinical Infectious Diseases, 1996; 23:577-84.

1. Hajjeh R et al for the Unexplained Deaths and Critical Illness Working Group.\* Surveillance for Unexplained Deaths and Critical Illnesses Due to Possibly Infectious Causes, United States, 19951998. Emerging Infectious Diseases, 2002; 8:1-17.
2. Backman L, Brett-Smith H, **Virata, M**. Knowledge and Attitude Related to Plasma HIV RNA Levels and CD4 Cell Counts in HIV Infected Individuals: A Patient Perspective Study. (Extended Abstract form). Monduzzi Editore, International Proceedings Division, for the XIV International AIDS Conference. July 2002
3. Moreno J, Chia D, Aronin S, Suarez R, **Virata M**, Igwe C, Quentzel H, Sadigh M. A Depiction of Imported Malaria in Connecticut. ID Cases, 2014 (1) p26-28.
4. Lombo B, Alkhalil I, Fotjadhi I, Ravi S, MD, **Virata M**, Lievano M, Diez J, Ghantous A, Thomas Donohue T. Prevalence of Metabolic Syndrome in Patients with HIV in the Era of Highly Active Antiretroviral Therapy. CT Medicine, May 2015; p277-281.
5. Moise P, Culshaw D, Wong-Beringer A, Bensman J, Lamp K, Smith W, Bauer K, Goff D, Adamson R, Leuthner K, **Virata M**, McKinnell J, Chaudhry S, Eskandarian R, Lodise T, Reyes K, and Zervos

M. Comparative Effectiveness of High-Dose Vancomycin versus Early Daptomycin for MRSA Bacteremia with Vancomycin MIC >1 mg/L: A Multicenter Evaluation. Clin Ther. 2015 Nov 13. pii: S0149-2918(15)01148-0. doi: 10.1016/j.clinthera.2015.09.017.

1. Villanueva M, Malinis M, **Virata M**, Hao R, Ogbuagu O. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017.
2. Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, **Virata M**, Brown ST, Justice AC, Bryan K, Fiellin DA, and Fiellin LE. Efficacy of extended-release naltrexone on HIV-related and drinking outcomes among HIV-positive patients: A randomized-controlled trial. AIDS and Behavior, Aug 2018
3. Hysell K, Yusuf R, Barakat L, **Virata M**, Gan G, Deng Y, Perez-Irizarry J, VegaT, Goldberg SB, Emu B, Decreased Overall Survival in HIV-Associated Non Small Cell Lung Cancer. Clinical Lung Cancer (2021), doi: <https://doi.org/10.1016/j.cllc.2020.11.006>.
4. **Virata M**, Shenoi S, Ladines-Lim J, Villanueva MS, Lydia A. Barakat LA. Increasing Numbers of Non-communicable Disease Co-morbidities: Major Risk Factors for Hospitalization among a Cohort of People with HIV and COVID-19 Coinfection. medRxiv 2021.08.03.21261560; doi: <https://doi.org/10.1101/2021.08.03.21261560>
5. **Virata M**, Shenoi SV, Ladines-Lim J, Villanueva MS, Barakat LA (2021) Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study. PLoS ONE 16(12): e0260251. <https://doi.org/10.1371/journal.pone.0260251>
6. Morford KL, Muvvala SB, Chan PA, Cornman DH, Doernberg M, Porter E, **Virata M**, Yager JE, Fiellin DA, Edelman EJ. Patients’ perspectives of medications for addiction treatment in HIV clinics: A qualitative study. Journal of Substance Abuse Treatment. Mar 2022 <https://doi.org/10.1016/j.jsat.2022.108767>
7. Shresta R, Meyer JP, Shenoi S, Khati A, Altice FL, Mistler C, Aoun-Barakat L, **Virata M**, Olivares M, Maviglia F, Wickersham J. COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey. <https://doi.org/10.3390/>. Vaccines 2022.
8. Wickersham J, Meyer JP, Shenoi S, Altice FL, Aoun-Barakat L, **Virata M**, Olivares M, Maviglia F, Khati A, Shresta R. Willingness to be vaccinated against COVID-19 people with HIV in the United States. Frontiers in Medicine, June 2022.
9. Kahn PA, Ying X, **Virata M**, Magahis P, Li S, Mathis WS. Availability and Accessibility of Live Nonreplicating Smallpox/Mpox Vaccine. JAMA Network Open. 2023 Apr 3;6(4):e237873. doi: 10.1001/jamanetworkopen.2023.7873. PMID: 37027158; PMCID: PMC10082399.
10. Gleeson SE, Zapata H, Bathgate ME, Emu B, Frederick J, Friedland G, Golden MP, Meyer JP, Radin J, Sideleau R, Shaw A, Shenoi SV, Trubin PA, **Virata M**, Barakat LA, Desruisseaux MS. Building an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center’s Experience and Reflections. Clin Infect Dis. 2023 Sep 11;77(5):703-710. doi: 10.1093/cid/ciad236.PMID: 37078888
11. Strong SH, Oldfield BJ, van den Berg JJ, Cole CA, Biegacki E, Ogbuagu O, **Virata M**, Chan PA, Edelman EJ.  Perspectives on unhealthy alcohol use among men who have sex with men prescribed HIV pre-exposure prophylaxis: A qualitative study. Prev Med Rep. 2023 Dec 10;37:102553. doi: 10.1016/j.pmedr.2023.102553. eCollection 2024 Jan.PMID: 38282665

**Case Reports, Technical Notes, Letters**

1. **Virata M**, Rosenstein N, Hadler J, Barrett N, Tondella M, Mayer L, Weyant R, Hill B, Perkins B.

Suspected Brazilian Purpuric Fever in a Toddler with Overwhelming, Epstein-Barr Virus Infection. Clinical Infectious Diseases, 1998. (Nov) Pp. 1328-1330.

1. Gnanaraj J, Fiedler P, **Virata M.**  Vanishing Bile Duct Syndrome in a HIV Patient on HAART Therapy. Accepted for epub as a case report for BMJ Case Reports, Sept. 2011.